Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt & H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt

EU orphan designation number: EU/3/07/521   
Active ingredient: H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt & H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt
Indication: Treatment of TERT positive non-small cell lung cancer in HLA-A2 positive patients
Sponsor: Vaxon Biotech
CIT BP 191, 3 rue de l'Arrivée, F-75749 Paris CEDEX 15, France

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
20/12/2007 Centralised Orphan - Designation EMEA/OD/081/07 (2007)6738 of 18/12/2007
25/11/2008 Other procedure
22/06/2010 Other procedure EMA/OD/081/07